Immunocore Holdings Announces Data Form Its Phase 1/2 Study Of Brenetafusp Shows 29% Overall Response Rate, 71% Disease Control Rate
Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve
Immunocore's new medicine helped nearly 3 in 10 patients with their disease. When a company shows real progress in testing, it suggests the medicine might actually work.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.